Ligand Pharmaceuticals | LGND - Cost Of Sales


Ligand Pharmaceuticals reported $11.37M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
Agenus USD 642K 399K Sep/2025
Amgen USD 1.6B 187M Mar/2026
Anika Therapeutics USD 11.44M 797K Dec/2025
Baxter International USD 1.81B 587M Mar/2026
Bristol-Myers Squibb USD 3.86B 1.07B Mar/2026
Eli Lilly USD 3.58B 205M Mar/2026
Enviri Corporation USD 472M 17.65M Dec/2025
Gilead Sciences USD 1.44B 174M Mar/2026
GlaxoSmithKline GBP 1.88B 736M Mar/2026
Glaxosmithkline GBP 1.88B 1.6B Mar/2026
Heron Therapeutics USD 11.12M 795K Dec/2025
Insmed USD 49.5M 3.34M Mar/2026
Intrexon USD 1.01M 344K Jun/2024
Ionis Pharmaceuticals USD 3M 5M Mar/2026
Karyopharm Therapeutics USD 1.48M 35.95M Dec/2025
Ligand Pharmaceuticals USD 11.37M 8.38M Mar/2026
MacroGenics USD 9.53M 585K Mar/2026
Merck USD 2.94B 380M Mar/2026
Pacira USD 50.74M 3.89M Mar/2026
Pfizer USD 4.59B 1.7B Mar/2026
Rigel Pharmaceuticals USD 8.03M 5.22M Sep/2024
Sangamo BioSciences 2.42M 1.11M Jun/2024
Veracyte USD 38.49M 794K Mar/2026